Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MOTRIN IB vs JUNIOR STRENGTH ADVIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Relief of minor aches and pains due to headache, toothache, backache, menstrual cramps, muscle aches, or minor pain of arthritis,Reduction of fever
FDA-labeled: Temporary relief of minor aches and pains (e.g., headache, toothache, menstrual cramps, muscle aches, backache),Fever reduction,Off-label: Osteoarthritis, rheumatoid arthritis (in higher doses),Off-label: Patent ductus arteriosus closure in neonates
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg in 24 hours.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.
Terminal elimination half-life is approximately 2 hours (range 1.8–2.5 hours) in adults. In patients with hepatic impairment or advanced age, half-life may be prolonged. The short half-life supports dosing every 6–8 hours for analgesia.
2-4 hours (terminal); prolonged in hepatic impairment and elderly.
Primarily hepatic via cytochrome P450 2C9 (CYP2C9) and, to a lesser extent, CYP2C8; undergoes glucuronidation.
Hepatic metabolism primarily via CYP2C9; also involves glucuronidation; major metabolites are hydroxylated and carboxylated forms.
Renal excretion of conjugated metabolites (primarily glucuronide and sulfate) accounts for approximately 90% of an absorbed dose; less than 1% is excreted unchanged. Biliary/fecal elimination constitutes about 10%.
Primarily renal (90% as glucuronide conjugates and 10% unchanged); <5% biliary/fecal.
Approximately 99% bound to plasma albumin.
90-99% bound to albumin; concentration-dependent.
Apparent volume of distribution is 0.15 L/kg (range 0.10–0.20 L/kg), consistent with low tissue penetration and high plasma protein binding.
0.1-0.2 L/kg (low, consistent with high protein binding).
Oral: ~80% (rapidly and completely absorbed; first-pass metabolism reduces absolute bioavailability to 80% of the dose).
Oral: 85-95% (ibuprofen susp/liquid); 80-100% (tablets/capsules).
GFR 30-60 m L/min: no adjustment needed; GFR 10-29 m L/min: reduce dose by 25-50%; GFR <10 m L/min: avoid use or reduce dose by 50%.
e GFR 30-60 m L/min: reduce dose by 50% or extend interval to q8-12h; e GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use.
6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; maximum 40 mg/kg/day or single doses not exceeding 400 mg.
5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day (or 1200 mg/day) for children ≥6 months.
Initiate at the lowest effective dose, typically 200-400 mg every 6-8 hours; maximum 1200 mg/day; monitor renal function and potential for GI bleeding.
Start at lowest effective dose (200 mg q6-8h); maximum 1200 mg/day; monitor renal function and GI bleeding risk.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk. Additionally, NSAIDs cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
No FDA boxed warning for JUNIOR STRENGTH ADVIL (ibuprofen). However, NSAIDs in general carry a boxed warning for cardiovascular thrombotic events and gastrointestinal bleeding.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; heart failure; renal toxicity; anaphylactoid reactions; serious skin reactions such as Stevens-Johnson syndrome; avoid use in late pregnancy
Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke,Gastrointestinal risk: Increased risk of GI bleeding, ulceration, and perforation,Renal effects: May cause renal impairment, especially in patients with pre-existing renal disease,Hypersensitivity reactions: Anaphylaxis, bronchospasm,Fluid retention and edema,Avoid use with other NSAIDs or in late pregnancy (risk of premature closure of ductus arteriosus)
Hypersensitivity to ibuprofen or any component of the formulation; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; active peptic ulcer or gastrointestinal bleeding; advanced renal disease
Hypersensitivity to ibuprofen or any component of the formulation,Asthma, urticaria, or allergic-type reactions after aspirin or other NSAID use,Treatment of perioperative pain in coronary artery bypass graft (CABG) surgery,Use in children with chickenpox (due to increased risk of severe skin reactions)
Concomitant intake of alcohol may increase risk of gastrointestinal bleeding. No specific food restrictions; however, taking with food may reduce GI irritation. Avoid grapefruit juice? No significant interaction known.
Avoid alcohol: increases risk of GI bleeding. Limit caffeine as may increase side effects. Can be taken with food or milk to minimize GI irritation.
First trimester: Increased risk of miscarriage and cardiac defects (odds ratio 1.86 for cardiovascular malformations). Second trimester: Risk of oligohydramnios and fetal renal dysfunction. Third trimester: Known risk of premature closure of ductus arteriosus, persistent pulmonary hypertension, oligohydramnios, and necrotizing enterocolitis. Use contraindicated after 30 weeks gestation.
Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly needed; limited human data suggest low risk of major malformations but increased risk of miscarriage and cardiac defects.
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01). Amount ingested by infant <1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for gastrointestinal effects and renal function.
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01). Not expected to cause adverse effects in infants with short-term use at recommended doses. Avoid in nursing mothers breastfeeding preterm or low-birth-weight infants.
Increased volume of distribution and renal clearance in pregnancy may reduce serum concentrations. However, due to fetal risks, dose adjustments are not recommended; instead, avoid use after 30 weeks and limit to lowest effective dose with shortest duration in earlier trimesters.
No specific dose adjustment recommended in pregnancy. However, use lowest effective dose for shortest duration. In third trimester, avoid use unless benefit outweighs risk of fetal toxicity.
Motrin IB (ibuprofen) is a nonsteroidal anti-inflammatory drug (NSAID) used for mild to moderate pain, fever, and inflammation. Onset of analgesia is within 30-60 minutes. It is more effective than acetaminophen for inflammatory pain. Maximum single OTC dose is 400 mg; maximum daily OTC dose is 1200 mg. Chronic use increases risk of GI bleeding, renal impairment, and cardiovascular events. Avoid in patients with significant renal impairment (e GFR <30), active peptic ulcer disease, or prior hypersensitivity to NSAIDs. Use with caution in patients with hypertension, heart failure, or on anticoagulants. Ibuprofen may reduce the cardioprotective effect of low-dose aspirin if taken simultaneously; separate dosing by at least 2 hours.
For pediatric patients, weight-based dosing is critical; typical dose is 5-10 mg/kg/dose every 6-8 hours. Avoid use in children with dehydration, bleeding disorders, or aspirin allergy. May mask signs of infection. Not recommended for children under 6 months.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg (6 tablets of 200 mg) in 24 hours.,Avoid alcohol while taking this medication to reduce risk of stomach bleeding.,Stop use and consult a doctor if pain worsens or lasts more than 10 days, or if fever lasts more than 3 days.,Do not take with other NSAIDs (e.g., naproxen, aspirin) unless directed by a healthcare provider.,Seek medical attention immediately if signs of allergic reaction (rash, hives, swelling, difficulty breathing) or stomach bleeding (black/bloody stools, vomiting blood) occur.
Give with food or milk to reduce stomach upset.,Do not exceed recommended dose; overdose can cause liver damage or gastrointestinal bleeding.,Do not use with other products containing ibuprofen or NSAIDs.,Shake suspension well before measuring dose using appropriate dosing device.,Stop use and consult doctor if symptoms worsen or new symptoms occur.,Keep out of reach of children; in case of overdose, contact Poison Control immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MOTRIN IB vs JUNIOR STRENGTH ADVIL, answered by our medical review team.
MOTRIN IB is a NSAID Analgesic that works by Reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. JUNIOR STRENGTH ADVIL is a NSAID Analgesic that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MOTRIN IB and JUNIOR STRENGTH ADVIL depend on the specific clinical indication. These are both NSAID Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MOTRIN IB is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg in 24 hours.. The standard adult dose of JUNIOR STRENGTH ADVIL is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MOTRIN IB and JUNIOR STRENGTH ADVIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MOTRIN IB is classified as Category C. First trimester: Increased risk of miscarriage and cardiac defects (odds ratio 1.86 for cardiovascular malformations). Second trimester: Risk of oligohydramnios and fetal renal dys. JUNIOR STRENGTH ADVIL is classified as Category C. Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly nee. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.